Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.

Stemmer SM, Benjaminov O, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, Patoka R, Singer B, Kerns WD, Fishman P.

Oncologist. 2013;18(1):25-6. doi: 10.1634/theoncologist.2012-0211. Epub 2013 Jan 8.

2.

Rapid induction of colonic adenocarcinoma in mice exposed to benzo[a]pyrene and dextran sulfate sodium.

Hakura A, Seki Y, Sonoda J, Hosokawa S, Aoki T, Suganuma A, Kerns WD, Tsukidate K.

Food Chem Toxicol. 2011 Nov;49(11):2997-3001. doi: 10.1016/j.fct.2011.07.057. Epub 2011 Jul 30.

PMID:
21827817
3.

Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.

Avni I, Garzozi HJ, Barequet IS, Segev F, Varssano D, Sartani G, Chetrit N, Bakshi E, Zadok D, Tomkins O, Litvin G, Jacobson KA, Fishman S, Harpaz Z, Farbstein M, Yehuda SB, Silverman MH, Kerns WD, Bristol DR, Cohn I, Fishman P.

Ophthalmology. 2010 Jul;117(7):1287-93. doi: 10.1016/j.ophtha.2009.11.029. Epub 2010 Mar 20.

4.

Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.

Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, Rosner I, Rozenbaum M, Mader R, Adawi M, Caspi D, Tishler M, Langevitz P, Rubinow A, Friedman J, Green L, Tanay A, Ochaion A, Cohen S, Kerns WD, Cohn I, Fishman-Furman S, Farbstein M, Yehuda SB, Fishman P.

J Rheumatol. 2008 Jan;35(1):41-8. Epub 2007 Nov 15.

PMID:
18050382
5.

The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis.

Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, Fishman P.

Expert Opin Investig Drugs. 2007 Oct;16(10):1601-13. Review.

PMID:
17922624
6.

Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity.

Dietsch GN, Dipalma CR, Eyre RJ, Pham TQ, Poole KM, Pefaur NB, Welch WD, Trueblood E, Kerns WD, Kanaly ST.

Toxicol Pathol. 2006;34(1):39-51.

PMID:
16507543
7.

Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.

van Troostenburg AR, Clark EV, Carey WD, Warrington SJ, Kerns WD, Cohn I, Silverman MH, Bar-Yehuda S, Fong KL, Fishman P.

Int J Clin Pharmacol Ther. 2004 Oct;42(10):534-42.

PMID:
15516022
8.

Cardiovascular assessment of ER-118585, a selective phosphodiesterase 5 inhibitor.

Mizuno H, Adachi H, Kimura J, Sawa Y, Kakiki M, Lansdell K, Saito M, Kerns WD.

Biol Pharm Bull. 2003 Dec;26(12):1661-7.

9.

Use of human liver S9 in the Ames test: assay of three procarcinogens using human S9 derived from multiple donors.

Hakura A, Suzuki S, Sawada S, Sugihara T, Hori Y, Uchida K, Kerns WD, Sagami F, Motooka S, Satoh T.

Regul Toxicol Pharmacol. 2003 Feb;37(1):20-7.

PMID:
12662906
10.

Hypocholesterolaemic and antiatherosclerotic effects of tetra-iso-propyl 2-(3,5-di-tert-butyl-4-hydroxyphenyl)ethyl-1,1-diphosphonate (SR-9223i).

Jackson B, Gee AN, Guyon-Gellin Y, Niesor E, Bentzen CL, Kerns WD, Suckling KE.

Arzneimittelforschung. 2000 Apr;50(4):380-6.

PMID:
10800637
11.

Multiple organ mutation in the lacZ transgenic mouse (Muta mouse) 6 months after oral treatment (5 days) with benzo[a]pyrene.

Hakura A, Tsutsui Y, Sonoda J, Mikami T, Tsukidate K, Sagami F, Kerns WD.

Mutat Res. 1999 May 3;426(1):71-7.

PMID:
10320752
12.

SR-12813 lowers plasma cholesterol in beagle dogs by decreasing cholesterol biosynthesis.

Berkhout TA, Simon HM, Jackson B, Yates J, Pearce N, Groot PH, Bentzen C, Niesor E, Kerns WD, Suckling KE.

Atherosclerosis. 1997 Sep;133(2):203-12.

PMID:
9298680
13.

Single-organism model of host defense against infection: a novel immunotoxicologic approach to evaluate immunomodulatory drugs.

Herzyk DJ, Ruggieri EV, Cunningham L, Polsky R, Herold C, Klinkner AM, Badger A, Kerns WD, Bugelski PJ.

Toxicol Pathol. 1997 Jul-Aug;25(4):351-62.

PMID:
9280118
14.

A novel technique for mapping the lipid composition of atherosclerotic fatty streaks by en face fluorescence microscopy.

Klinkner AM, Bugelski PJ, Waites CR, Louden C, Hart TK, Kerns WD.

J Histochem Cytochem. 1997 May;45(5):743-53.

PMID:
9154162
15.

Spontaneous and induced alterations in the cardiac membranous ventricular septum of fetal, weanling, and adult rats.

Solomon HM, Wier PJ, Fish CJ, Hart TK, Johnson CM, Posobiec LM, Gowan CC, Maleeff BE, Kerns WD.

Teratology. 1997 Mar;55(3):185-94.

PMID:
9181672
16.
17.

Evidence of foam cell and cholesterol crystal formation in macrophages incubated with oxidized LDL by fluorescence and electron microscopy.

Klinkner AM, Waites CR, Kerns WD, Bugelski PJ.

J Histochem Cytochem. 1995 Oct;43(10):1071-8.

PMID:
7560885
18.

Chemical-induced vasculature injury. Summary of the symposium presented at the 32nd annual meeting of the Society of Toxicology, New Orleans, Louisiana, March 1993.

Boor PJ, Gotlieb AI, Joseph EC, Kerns WD, Roth RA, Tomaszewski KE.

Toxicol Appl Pharmacol. 1995 Jun;132(2):177-95.

PMID:
7785047
19.

Separation of immunomodulatory and cholesterol-lowering activities of heterocyclic azaspiranes.

Albrightson CR, Bugelski PJ, Berkhout TA, Jackson B, Kerns WD, Organ AJ, Badger AM.

J Pharmacol Exp Ther. 1995 Feb;272(2):689-98.

PMID:
7853183
20.

The application of toxicokinetic data to dosage selection in toxicology studies.

Morgan DG, Kelvin AS, Kinter LB, Fish CJ, Kerns WD, Rhodes G.

Toxicol Pathol. 1994 Mar-Apr;22(2):112-23.

PMID:
7973359
22.

Effects of laser thermal angioplasty on arterial contractions and mechanics.

Consigny PM, Teitelbaum GP, Gardiner GA Jr, Kerns WD.

Cardiovasc Intervent Radiol. 1989 Mar-Apr;12(2):83-7.

PMID:
2525418
23.

Pathogenesis of arterial lesions induced by dopaminergic compounds in the rat.

Kerns WD, Arena E, Macia RA, Bugelski PJ, Matthews WD, Morgan DG.

Toxicol Pathol. 1989;17(1 Pt 2):203-13.

PMID:
2568682
24.

More precise localization of nasal tumors associated with chronic exposure of F-344 rats to formaldehyde gas.

Morgan KT, Jiang XZ, Starr TB, Kerns WD.

Toxicol Appl Pharmacol. 1986 Feb;82(2):264-71.

PMID:
3945953
25.

The embryo-fetal toxicity and teratogenic potential of ammonium perfluorooctanoate (APFO) in the rat.

Staples RE, Burgess BA, Kerns WD.

Fundam Appl Toxicol. 1984 Jun;4(3 Pt 1):429-40.

PMID:
6745532
26.

Carcinogenicity of formaldehyde in rats and mice after long-term inhalation exposure.

Kerns WD, Pavkov KL, Donofrio DJ, Gralla EJ, Swenberg JA.

Cancer Res. 1983 Sep;43(9):4382-92.

27.

Induction of squamous cell carcinomas of the rat nasal cavity by inhalation exposure to formaldehyde vapor.

Swenberg JA, Kerns WD, Mitchell RI, Gralla EJ, Pavkov KL.

Cancer Res. 1980 Sep;40(9):3398-402.

Supplemental Content

Loading ...
Support Center